デフォルト表紙
市場調査レポート
商品コード
1719237

レボドパ市場- 世界の市場規模、シェア、動向、機会、予測、販売チャネル別、最終用途別、地域別、競合別、2020-2030年

Levodopa Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.34円
代理店手数料はかかりません

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

レボドパ市場- 世界の市場規模、シェア、動向、機会、予測、販売チャネル別、最終用途別、地域別、競合別、2020-2030年
出版日: 2025年04月30日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

レボドパの世界市場は、2024年には1億7,371万米ドルと評価され、2030年には2億7,153万米ドルに達すると予測され、予測期間中のCAGRは5.36%で成長すると予測されています。

レボドパは、パーキンソン病やパーキンソニズムに伴う運動症状を管理するための基礎治療であり、患者の生活の質を大幅に改善します。主に60歳以上のパーキンソン病有病者の世界の増加は、市場の需要を促進する大きな要因です。世界保健機関（WHO）によると、現在600万人以上がパーキンソン病を患っており、この数は高齢化とともに増加すると予測されています。その結果、レボドパに基づく治療に対するニーズは拡大し続けています。Sinemetのような先発医薬品は高いブランド認知度を維持していますが、費用対効果の高いジェネリック医薬品の採用が増加しており、特に価格に敏感な新興地域において、市場力学が再構築されつつあります。

市場概要
予測期間 2026-2030
市場規模：2024年 1億7,371万米ドル
市場規模：2030年 2億7,153万米ドル
CAGR：2025年～2030年 5.36%
急成長セグメント ダイレクト
最大市場 北米

市場促進要因

ヘルスケア産業の成長

主な市場課題

副作用と長期使用に関する懸念

主要市場動向

長時間作用型製剤と非経口製剤への注目の高まり

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界のレボドパ市場に与える影響

第5章 世界のレボドパ市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 販売チャネル別（直接、間接）
    • 用途別（パーキンソン病、むずむず脚症候群、ジスキネジア管理、アルツハイマー病、その他）
    • 地域別
    • 企業別（2024）
  • 市場マップ

第6章 北米のレボドパ市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州のレボドパ市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域のレボドパ市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米のレボドパ市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのレボドパ市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収
  • 製品上市
  • 最近の動向

第13章 世界のレボドパ市場：SWOT分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 競合情勢

  • Shandong Xinhua Pharmaceutical Co., Ltd.
  • Wild Wind Pharmaceutical
  • Zhejiang Huahai Pharmaceutical
  • Zhejiang Yefeng Pharmaceutical Co., Ltd
  • SHADRI LAB PRIVATE LTD
  • Divi's Laboratories Limited
  • Zhejiang Zhenyuan Co., Ltd.
  • EMBIO LIMITED
  • J.K. LIFECARE CENTERS PVT. LTD
  • Hetero Drugs Limited

第16章 戦略的提言

第17章 調査会社について・免責事項

目次
Product Code: 28581

The Global Levodopa Market was valued at USD 173.71 Million in 2024 and is anticipated to reach USD 271.53 Million by 2030, growing at a CAGR of 5.36% during the forecast period. Levodopa remains a foundational treatment for managing motor symptoms associated with Parkinson's disease and parkinsonism, offering substantial improvements in patients' quality of life. The global rise in Parkinson's disease prevalence-primarily among individuals aged 60 and above-is a major factor fueling market demand. According to the World Health Organization (WHO), over 6 million people currently live with Parkinson's disease, a number projected to grow alongside aging populations. As a result, the need for levodopa-based therapies continues to expand. While branded drugs like Sinemet retain strong brand recognition, increasing adoption of cost-effective generics is reshaping market dynamics, especially in price-sensitive emerging regions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 173.71 Million
Market Size 2030USD 271.53 Million
CAGR 2025-20305.36%
Fastest Growing SegmentDirect
Largest MarketNorth America

Key Market Drivers

Growth in Healthcare Industry

The global increase in healthcare expenditure is a key factor supporting the levodopa market, particularly in the context of chronic neurological disease management. With healthcare spending reaching USD 9.8 trillion in 2021-accounting for 10.3% of global GDP-governments and private institutions are prioritizing resource allocation for conditions such as Parkinson's disease. Despite such investments, life expectancy remains static in several countries, reinforcing the need for effective chronic care solutions. Levodopa remains the most prescribed therapy for Parkinson's symptoms, and improved healthcare infrastructure-particularly in Asia-Pacific and Latin America-is expanding access to this essential medication. As neurological diseases affect over 3 billion people globally, rising per capita healthcare investment is enabling wider use of levodopa across both established and emerging markets.

Key Market Challenges

Side Effects and Long-Term Use Concerns

A key challenge limiting the long-term use of levodopa is the occurrence of motor complications, such as dyskinesia and motor fluctuations, with prolonged therapy. Although levodopa delivers significant early-stage symptom relief, long-term administration can lead to "on-off" episodes and reduced therapeutic consistency. These adverse effects are caused by fluctuating dopamine levels and can substantially diminish quality of life for advanced-stage patients. Consequently, reliance on levodopa monotherapy decreases over time, pushing the need for combination therapies or reformulated drugs that offer more stable symptom management. These side effects pose significant limitations for clinicians and patients, impacting treatment planning and adherence.

Key Market Trends

Increased Focus on Long-Acting and Non-Oral Formulations

The shift toward long-acting and alternative delivery formulations is becoming a prominent trend in the levodopa market. Traditional oral levodopa often requires multiple doses per day, leading to patient compliance challenges and inconsistent symptom control. Innovations such as extended-release formulations and non-oral delivery systems are designed to address these issues by offering sustained therapeutic effects and improved adherence. For instance, Duodopa-a gel-based levodopa administered via an infusion pump and PEJ tube-provides continuous drug delivery for advanced Parkinson's patients experiencing severe motor fluctuations. These solutions reduce the frequency of dosing and stabilize dopamine levels, mitigating the "on-off" phenomenon. As a result, long-acting options are gaining traction in clinical practice and are expected to contribute significantly to future market growth.

Key Market Players

  • Shandong Xinhua Pharmaceutical Co., Ltd.
  • Wild Wind Pharmaceutical
  • Zhejiang Huahai Pharmaceutical
  • Zhejiang Yefeng Pharmaceutical Co., Ltd
  • SHADRI LAB PRIVATE LTD
  • Divi's Laboratories Limited
  • Zhejiang Zhenyuan Co., Ltd.
  • EMBIO LIMITED
  • J.K. LIFECARE CENTERS PVT. LTD
  • Hetero Drugs Limited

Report Scope

In this report, the Global Levodopa Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Levodopa Market, By Sales Channel:

  • Direct
  • Indirect

Levodopa Market, By End Use:

  • Parkinson's Disease
  • Restless Legs Syndrome
  • Dyskinesia Management
  • Alzheimer's Disease
  • Others

Levodopa Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Levodopa Market.

Available Customizations

Global Levodopa Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Levodopa Market

5. Global Levodopa Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Parkinson's Disease, Restless Legs Syndrome, Dyskinesia Management, Alzheimer's Disease, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Levodopa Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Levodopa Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Mexico Levodopa Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Canada Levodopa Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Levodopa Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Levodopa Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. Germany Levodopa Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Levodopa Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Levodopa Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Levodopa Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Levodopa Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Levodopa Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Levodopa Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. South Korea Levodopa Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. Japan Levodopa Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Levodopa Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. South America Levodopa Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Levodopa Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Levodopa Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Levodopa Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Levodopa Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Levodopa Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Levodopa Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Levodopa Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Levodopa Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Shandong Xinhua Pharmaceutical Co., Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Wild Wind Pharmaceutical
  • 15.3. Zhejiang Huahai Pharmaceutical
  • 15.4. Zhejiang Yefeng Pharmaceutical Co., Ltd
  • 15.5. SHADRI LAB PRIVATE LTD
  • 15.6. Divi's Laboratories Limited
  • 15.7. Zhejiang Zhenyuan Co., Ltd.
  • 15.8. EMBIO LIMITED
  • 15.9. J.K. LIFECARE CENTERS PVT. LTD
  • 15.10. Hetero Drugs Limited

16. Strategic Recommendations

17. About Us & Disclaimer